Raltegravir potassium is primarily used in the treatment of HIV-1 infection. It functions as an integrase inhibitor, blocking the integrase enzyme that the virus needs to replicate its genetic material into the DNA of human cells. By inhibiting this enzyme, it helps to reduce the viral load in the body and maintain a healthy immune system. It is often prescribed as part of a combination antiretroviral therapy (ART) to enhance its effectiveness and minimize the risk of developing drug resistance. This medication is particularly beneficial for patients who have developed resistance to other classes of antiretroviral drugs. It is available in both tablet and oral suspension forms, making it accessible for adults and pediatric patients. Regular monitoring of viral load and CD4 cell count is essential to assess the treatment's efficacy and make necessary adjustments.